Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Cinclus Pharma, Audiocast, Q2'25

By Inderes8/20/2025, 8:00 AM
Cinclus Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christer Ahlberg
00:01 - 12:25

Hello and welcome to Cinclus Pharma's second quarter 2025 earnings call. As already introduced, I'm Christer Ahlberg and I'm the CEO of Cinclus Pharma. And with me today is our CFO Maria Engström and Head of Corporate and Business Development Jesper Wiklund. We will present the latest developments from the second quarter 2025 and the upcoming news flow, after which we will be happy to answer any questions you might have. Before we begin, I would like to remind our listeners that during today's call, management may make forward-looking statements that involve known and unknown risks, uncertainties, and other important factors beyond the company's control that could cause the company's actual results, performance, or achievements to differ materially from the expected results, performance, or achievements expressed or implied by such forward-looking statements. So please take a moment to review that. And with those formalities out of the way, let me begin with a high-level overview of the company, including key business updates and investment highlights, before we go into other activities in this presentation. So what do you know about Cinclus Pharma? I mean, we are a Swedish pharmaceutical company, a late-stage development company headquartered in Stockholm and listed on Nasdaq Stockholm. We have the global rights for our lead candidate Linaprazan glurate, where we have our license and we have partners in Asia with Sinorda and a sublicense partner in China with Shanghai Pharma, and a recent partnership with Zentiva in Europe. We will address this further in the presentation. We will discuss more about that later in the presentation. Lina, as you know, is the next generation of PCABs with the potential to become best in class due to its unique 24-hour acid control. PCABs, as you're aware, represent the first innovation in the mechanism of action for gastric and acid-related disorders in over 25 years. We, as a company, are focusing intensely on the high unmet medical need in patients suffering from severe erosive GERD. These patients are treated by specialists, specifically gastroenterologists. And that enables us to have a specialty commercial focus, which has many advantages in this area. It also gives us a blockbuster potential. Our unique product provides a distinct pharmacokinetic and pharmacodynamic profile, leading to 24-hour acid control. And that gives us a very strong competitive edge and advantage compared to the old standard of care. Proton pump inhibitors, or PPIs, and the first generations of PCABs. I mean, we have a very fast onset. We have a long duration. We have a unique 24-hour acid control. Control gives us a superior healing capability, achieving results in half the time compared to other treatments. And our ambition is also to deliver superior symptom relief. We have already delivered very good data in the Phase II study, and we are now ready to start the Phase III trial. We are expecting the last responses from the authorities in the near term. And thereafter, we are ready to initiate and start up the study. So, everything is according to plan. We have, as we see it, and we have discussed that earlier. I mean, we have a very scientific as well as a clinically de-risked development program supported by all the proof of concept. We have very good Phase II data demonstrating good efficacy and safety. So this is the final plan moving forward with the phase three trial, and that is the first study that we will initiate. Now is the first out of two healing studies that needs to be done before a potential approval. It's also interesting to look at the market. Perhaps the first generation market is growing globally. We see that it has been launched in 30 countries globally and is definitely gaining traction in the erosive GERD and symptomatic GERD, but also in the guidelines, which is definitely important. We see them in the guidelines in Asia. We have also seen them included in the guidelines in the US recently. From a sales point of view, we also see very good growth in Japan, with close to 1 billion US dollars, and in South Korea, more than 200 million USD in sales, showing significant growth there. We also see a very good start for the first PCAB on the launch in the US, and there is also interesting growth of sales in South America, with a pricing point of view at $2 or $3 per tablet, which reflects very good and healthy pricing. And before we proceed, we want to provide you with some additional information about the treatment. The key to success in this area is to control acid production. The longer you can control the acid production and maintain a pH level above four in the stomach, the better the chances are to heal the patients. Actually, there is a linear correlation here. So if you can keep the pH above four 100%, Over a 24-hour period, if sustained for a longer duration, you will heal the patients. This disease is caused by acid. And what you do is to reduce it or get rid of it, and then you will heal the patients. It's not more complicated than that. Therefore, we think it would actually be interesting to plot the latest data from clinical studies into this linear line, as you can see. If you do that as an example, in the next slide, you can look at the latest Phase III trial from one study where they also have an acid control, PKC control of approximately 85%, and for the C and D patients over eight weeks, they delivered approximately a little bit more than 90%. And that's spot on the line here in the correlation that we have already shown in the same study. They compared themselves with lansoprazole 30mg, and they have 66% acid control. And if you look at the healing in these patients over eight weeks, it's also spot on the line in the correlation here. We know the latest PCAB in the US and Asia have less acid control than the earlier versions, with the control being below 80%. And we expect them to be around 80% of healing. It's very much perfectly fit into this line. Looking into our drug, we have 96% acid control. And if you just put it on the line there, we are then coming close to 100% healing. So this is interesting. Analysis to be done. And I just wanted to give you that information now, and the answer is yes. That's the reason why we think the biomarker with acid control is so important in this case. And that gives us an indication of what we can expect in the future. Summary of the key events for the quarter. Yes, we will tell you much more about the strategic alliance and license agreement with Zentiva, which gave us a deal value of €220 million in total, but also with a very good royalty of approximately 20%. Jesper will give you more information about that shortly. We have also received a waiver from both the EMA and FDA for the requirement to conduct pediatric studies of Linaprazan glurate for the treatment of Helicobacter pylori infection. Which, of course, gives us a better possibility to deliver that and make it more effective and faster. Uh, and also during the quarter, it has been clarified by the FDA that an indication with H. Pylori provides a five-year data exclusivity extension in the US for all indications for the substance if H pylori is chosen as the first indication. So that's a good clarification. Absolutely. We have also published the Phase II results demonstrating high healing rates. I mean, we are actually delivering 93% healing for severe patients in four weeks. We also deliver 100% healing of the partial responders after the PPI treatment. This is, of course, very supportive in the continued development of the rate. Also very promising, I would say, in relation to what I just mentioned about acid control. We have also participated in the largest congress in San Diego during the quarter, where we presented new data confirming the potent acid-blocking properties of Linaprazan glurate. And the promising results from the optimized tablet formulation that will now be used in Phase III and in the commercialization. Commercialization later on. We also. It's interesting to look at the market. Now it's generating more and more interest. Within the specialist community, there is growing interest in 'Heroes of Gold,' and we have been the main sponsor of the gastroenterology conference organized by specialists in this area. And that was in France. And now we will also focus on reflux diseases, which is, of course, a very good sign for the future, especially as we start to focus more on this. With that, I stop and hand over now to Jasper.

Operator
12:27 - 20:24

Okay. Thank you, Christer. So the partnership that we formed with Zentiva is for the commercialization and manufacturing of Linaprazan glurate in Europe. So we out-licensed the European rights in this deal. Most importantly, we really view this as a strategic alliance. And it's very much a very important transformation, really, of the company of Cinclus Pharma and our capabilities. If you look at it from a capability point of view, we, together with some of our partners with whom we have already developed a very close working relationship, now possess every single expertise needed to develop, register, and commercialize this product in Europe. We have this at a level which any company involved in this area would be very happy to have. It's a very strong set of capabilities that we have together with our partner. And this now maximizes both the likelihood of development success but also registration approval and commercialization. So it's really a de-risking from both a commercial and operational point of view, increasing the probability of us actually reaching and being successful in the market in Europe. And a few words about Zentiva. Zentiva is a very successful company now in Europe. They were formerly a part of Sanofi, were divested, and were actually bought by Advent International in 2018. So Advent, which, as everyone on this call I'm sure knows, is one of the world's foremost and leading private equity companies. Advent acquired essentially the manufacturing and generics business of Sanofi in 2018. Since then, together with the management team of Zentiva, they have created a very strong, operationally successful, execution-oriented company that now has a commercial presence in all relevant European markets. And they have a special focus in gastro and metabolic diseases. So it's really a perfect partner for us in terms of both where they are in their development and in terms of where they are commercially focused. We can say a few words here also about Zentiva. This was very much a validation for us regarding what we're doing, highlighting the commercial value and future positioning of our product. We know, of course, that there is no other PCAB currently being developed, registered, or prepared for commercialization in Europe. We know that since they have looked at every single PCAB, and they chose ours after a very significant due diligence. I mean, they were really involved, looking in detail for well over six months. It was an extremely thorough due diligence that turned over every single stone. And at the end of that, they came out and decided to go with us. Not because we're the furthest along—we're not—but because we're the best. And they really believe that in Europe, you need to have something that is truly a step forward and truly addressing the unmet medical need to have a strong commercial future and be able to obtain the necessary pricing. If we look at the deal value and some of the numbers, as Chris already mentioned, it's a 220 million total milestone deal, which is a very good number. These are divided into development milestones and commercial milestones. Most importantly though, if you believe in the commercial future of this product, as we do, we have a very attractive royalty rate. It's clustered around the 20% mark. It's a staggered royalty. Starting slightly below and ending slightly above 20%. But if one considers the profitability of a product like this in the European market, and you think about what 20% of net sales means, we are getting a very significant portion of the profitability of this product. And it's really a significant achievement. There is a comprehensive sharing of both the profits and the entire commercial future of the product. Importantly for us, of course, is that we had close to €20 million, approximately $20 million in upfront and near-term payments, €13 million of which were received as an upfront payment. We have already received that and an additional €5 million is forthcoming. Once we have delivered the first set of Phase III data, as mentioned, we retain full commercial rights outside of Europe, particularly in the United States. Of course, not in the territories that we've already licensed to Sinorda, but over the rest of the world, we retain full commercial rights. And if we take a step back and consider, what does this deal and these numbers guide us to or tell us about what a future deal might look like? Or what is the commercial value of this product in the United States, which is, of course, the largest remaining market that we still have 100% control over. We know that there's a multiple; the sales potential in the US is a multiple of the sales potential in Europe. That's a significant factor to take into account. The second point is that this deal was based on phase two data. We were able to demonstrate and present the phase two data. And based on that data, Zentiva, after their thorough due diligence, decided to do the deal. When we go out to look for commercialization partners or commercialization options based on the phase three data, it will be the next time that we do so. So we will then have phase three data, and we will have the remaining market being multiples higher than the current market. We believe that this indication provides some guidance on what the future might look like. If we were to do a deal for the US rights, as an indication of the importance of this to our company, such a deal could be sufficient to fund more than just the entire development programme all the way to approval. So that's one potential way that we can finance the entire development program. Given the fact that we already have enough resources and financing to see through this first Phase III trial. That could put us in a very interesting position from a financing point of view.

Christer Ahlberg
20:26 - 20:38

Okay, good. Yes. Should we go or is there anything else you wanted to mention? No, no. Okay. Then we go into the financials. Yes.

Operator
20:39 - 25:47

Thank you, Christer. So, the highlights for the quarter. Cash at the end of the period ended up at 589 million SEK, including, of course, the upfront payment from Zentiva of 12.4, post withholding taxes, while the R&D expenses ended up at 54 million SEK, driven by the Phase III preparation, which were a little bit higher in this quarter and included the CMC activities and also the completion of some preclinical studies. The R&D expenses as a percentage of OPEX was 86%, which was higher than the average over the past eight quarters. We also saw a slight increase in the number of employees, which is now 20. Additionally, we have 17 in-house consultants, bringing the total to 37 coworkers. And if we go to the next slide, where we see the year-over-year financials and the net sales, it was 34.1 compared to last year. This reflects the portion of the upfront payment from the contract that we recognized as income for the quarter. The remaining part of the upfront payment, which in total was 135.1 million SEK, will be prioritized during the course of the Phase III study. The operating expenses were -42.7 compared to last year. And as I already mentioned, that was due to the Phase III preparation being a little bit higher this quarter, also including the CMC activities and the finalization of the preclinical studies. The G&A expenses were also higher. And that was due to a one-time transaction expense for the Zentiva deal of 18.5 million. EBIT ended up at -8.6 million SEK compared to last year, reflecting the higher operating expenses, but also including the portion of the upfront payment as income. Financial net increased by 0.3 compared to last year, reflecting interest income on cash but offset by unrealized losses on current liabilities. Tax, as described in earlier calls, is due to corporate and cantonal tax obligations in our Swiss affiliate. Net profit ended up at -8.1 compared to last year, reflecting the impact of the one-time transaction expense from the same deal, as well as the revenue from the upfront payment and the higher R&D expenses. If we go to the balance sheet, then other current assets are positive 27.4 compared to last year; it mainly is prepayment with cash negative 95.8 compared to last year. Reflecting the ideal cash distribution, but also the Phase III higher spending. For the quarter, non-current liabilities, a new item here, increased by 63.8 compared to last year. And that relates to deferred revenue recognition from the Zentiva contract beyond one year. The current liabilities. For the same reason, it increased by 33.9 compared to last year, and that is titled short-term portion of the contract liability. So if we go to the next slide, we can see our shareholders at the end of June. The picture is pretty much the same as last quarter. We have our founders at the top, and our IPO cornerstone investor is still with us. And with this, I hand over to you, Christer, again.

Christer Ahlberg
25:48 - 26:03

Okay, thank you, Maria. And here you have some important dates for your diary. And with that, I will continue to the Q&A session.

Operator
26:09 - 26:29

If you wish to ask a question, please dial the Pound Key and then five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Arvid Kinder from DNB Carnegie. Please go ahead.

Christer Ahlberg
26:32 - 27:27

Good morning and thanks for taking my questions. So first off, it's good to see that preparations are finally coming to an end. But just to clarify, I think last quarter, you said the study would start in Q3. Is this still the target? Second, it seems Fadden has shifted their strategy to focus more on GIS where they've had much better success. On the one hand, I guess this would be supportive of your approach. On the other hand, it could mean that Fathom secures a stronger position in this setting ahead of your launch. Could you perhaps comment a little bit on how you see this impacting you? Do you expect to be able to convert a meaningful share of patients already on Leczna, or do you expect most patients starting treatment with LG to be new prescriptions altogether? Thank you.

Operator
27:28 - 31:02

Yes. Okay, let's start with the first question. That's very easy. Yes, we are still working on the targets. So no changes there. I mentioned initially that we are expecting the final response from the authorities in the near term, and thereafter we are ready to proceed. Second question regarding, and definitely, we have also seen the change of strategy within Fathom, and we understand them. Because when you're starting a new area after more than two decades of silence, it's crucial to have a well-defined strategy. Of course, you need to take it with a top-down strategy, starting with specialists and then spreading it to more general practitioners thereafter. So that's how you do it in pharma launch. And I understand that they are now starting to work towards that strategy. With that said, I think they will be successful, and that's good for us as well. Perhaps they will eventually replace PPIs. And you have seen it in so many markets. It's just a matter of time. What you can say about, I mean, of course, if they now go in our direction with a more specialized strategy. Then, of course, it is important to look into the market. And the market is definitely big enough to feed more than one player, especially due to two different reasons. I would say, if you can deliver the best in class, which we are confident we can deliver with the best acid control, which we have discussed so many times now, that will give us a unique position among the specialists. When it comes to the market dynamics, even though. There are so many patients that will relapse even with the current treatment options. We can also see in their studies that 25% of the severe patients are relapsing within six months with one of our own. So, there will be many different switch opportunities here for us even though we come in years after them, especially if we can deliver the best acid control, which is the holy grail for all specialists. They know that if you have the best acid control, then definitely that is something that they want to use, especially for a patient who is actually relapsing. And so we are not worried about that. We think, though, it's very important that one person and Fadden succeed in us. And it will, of course, take some time for them because they are developing the market again. And that takes time, effort, and resources. So, that process will indeed take some time. But nevertheless, we want them to be successful.

Christer Ahlberg
31:06 - 31:09

Thank you very much for that. I'll jump back in the queue.

Operator
31:11 - 31:12

Any other questions?

Christer Ahlberg
31:13 - 31:18

The next question comes from Oscar Haven Lamb from Stifel. Please go ahead.

Operator
31:20 - 31:48

Yes, hi team. Thanks for taking my question. And first of all, congrats on the progress this quarter. So my question would be about the upcoming Phase III trial. So, you'll need to recruit 500 patients for this first Phase III. And you're still guiding for the topline data release around 2026. So, just wondering what your expectations are regarding the recruitment pace for the trial? Any past benchmarks or examples that could guide us in terms of pace, or weren't there any of that kind? Thank you.

Christer Ahlberg
31:49 - 33:05

Of course, we have learned a lot about the pace from the Phase II trial. And we have learned a little bit from the challenges there. And therefore, as you know, we have quite many sites, approximately over 100 sites. A little bit more than 500 patients. Uh, and then we also learned from the pace in both Sebelius and Fathom's Phase III trials. So we are quite updated on the pace. How long it takes. So, we are talking about a recruitment time of approximately a year, something along those lines. And then you can start to calculate with the sites, enrolling 500 patients in a year. So, it's less than one patient per site per month in terms of pace. So, I think we have a good margin. And of course, we are ready to start now with different motivational factors and actions to be taken to actually recruit as fast as possible.

Operator
33:09 - 33:10

Okay. Very clear. Thank you very much.

Christer Ahlberg
33:17 - 33:19

Anything. Any other questions?

Operator
33:19 - 33:24

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad.

Christer Ahlberg
33:32 - 33:35

I can add we have some questions.

Operator
33:35 - 33:40

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Christer Ahlberg
33:41 - 35:47

No, actually, we have some more questions. In the live chat here, there is a question regarding the time scale for commercialization in Europe. As we have said, we're expecting approval approximately in 2029-2030 in Europe. We are expecting a launch by then, by Zentiva. And then we have another question regarding the difference in design of Phase II and III. Regarding endpoints, I would say overall the endpoints and the design are aligned. The phase two trial was designed as an exploratory study. So it's a little bit different, but the endpoints are similar. We are expecting to repeat the outcome in the phase two trial. And that is what we are aiming for. In the phase two trial. Remember that we actually already delivered superior healing in four weeks compared to the PPI lansoprazole. And we are going to use the same comparator in this study. And we're going to look at healing in four weeks, but also in eight weeks. So that is definitely something that we just need to replicate as a result. And then of course we are adding other endpoints; we look into symptom relief. We are also exploring different types of symptom relief, which will be important differentiation factors in the future. But overall, I would say the phase two and phase three trials are similar. Okay, no other questions. Then I think we should stop there. And I thank you for your time. And I hope to see and talk to you soon again. Thank you. Bye bye and have a nice day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…